Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Q4 2024 vs. Q3 2024
How the institutions holding Intra-Cellular Therapies, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 356 | 8 | 387 | +39 |
| Shares | 97.2M | 849.8K | 96.8M | +437.4K (+0.5%) |
| Value | $7.12B | $73.5M | $8.08B | +$1.03B (+14.6%) |
8 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (69)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (30)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
Not filed for Q4 2024 yet (8)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Eagle Asset Management Inc | 624,759 | $57.0M |
| Raymond James & Associates | 158,852 | $11.6M |
| B. Metzler seel. Sohn & Co. Holding AG | 33,291 | $2.44M |
| Chartwell Investment Partners, LLC | 13,270 | $971.0K |
| ClariVest Asset Management LLC | 8,164 | $559.2K |
| Raymond James Financial Services Advisors, Inc. | 4,197 | $307.1K |
| PEAK6 Investments LLC | 4,049 | $296.3K |
| Raymond James Trust N.A. | 3,199 | $234.1K |